STAT Plus: Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response
Buoyed by newly published, early data on its experimental Covid-19 vaccine, Moderna on Wednesday cracked onto the list of the 20 most valuable biopharma companies, as measured by market capitalization.
Moderna — $31 billion market value — is the only drugmaker in the Top 20 without an approved product. That is a remarkable achievement, especially for a company pursuing an unproven messenger RNA technology. It’s also a depressing indictment of the U.S. response to the pandemic.
Continue to STAT Plus to read the full story…
